GlaxoSmithKline PLC ADR Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 79 trades in GlaxoSmithKline PLC ADR (NYSE: GSK) since 2014, across 23 members, worth an estimated $1.4M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 52 buys against 27 sells, a modestly buy-led skew, with Democratic members responsible for 18% of the trades and Republican members 82%. The most recent disclosure shown was filed November 2025, and Lisa Mcclain has filed the most GSK transactions among those shown, with 6. Other recent filers include Valerie Hoyle and Robert B. Aderholt. One notable disclosed move was a purchase by Lisa Mcclain on August 4, 2025, up 36.9% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the GlaxoSmithKline PLC ADR (GSK) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
GlaxoSmithKline PLC ADR congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | |
|---|---|---|---|---|---|---|---|
 Lisa Mcclain House | Nov 21, 2025 | Oct 31, 2025 | 21 days | SELL |  $1,001 - $15,000 | +8.88% | |
Lisa Mcclain House | Nov 21, 2025 | Oct 30, 2025 | 22 days | BUY | $1,001 - $15,000 | +8.69% | |
Lisa Mcclain House | Nov 21, 2025 | Oct 30, 2025 | 22 days | SELL | $1,001 - $15,000 | +8.69% | |
 Valerie Hoyle House | Oct 10, 2025 | Sep 23, 2025 | 17 days | SELL | $1,001 - $15,000 | +25.91% | |
Lisa Mcclain House | Sep 12, 2025 | Aug 4, 2025 | 39 days | BUY | $1,001 - $15,000 | +36.90% | |
 Robert B. Aderholt House | Sep 10, 2025 | Jul 28, 2025 | 44 days | SELL | $1,001 - $15,000 | +37.74% | |
Lisa Mcclain House | Aug 13, 2025 | Jun 24, 2025 | 50 days | SELL | $1,001 - $15,000 | +33.36% | |
Lisa Mcclain House | Aug 13, 2025 | Jun 17, 2025 | 57 days | BUY | $1,001 - $15,000 | +29.87% |
GlaxoSmithKline PLC ADR (GSK) congressional trading FAQ
Can members of Congress legally trade GlaxoSmithKline PLC ADR (GSK) stock?
Yes. Members of Congress are permitted to trade individual stocks, including GlaxoSmithKline PLC ADR (GSK), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. BullishWhales tracks those disclosures; it does not imply any trade was improper.
Are congressional GlaxoSmithKline PLC ADR (GSK) trades public?
Yes. Every congressional trade in GlaxoSmithKline PLC ADR (GSK) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded GlaxoSmithKline PLC ADR (GSK)?
Members of Congress have disclosed 79 trades in GlaxoSmithKline PLC ADR (GSK) worth $1.4M across 23 members, according to public STOCK Act filings.
Which members of Congress have traded GlaxoSmithKline PLC ADR (GSK)?
Recent and active filers of GlaxoSmithKline PLC ADR (GSK) disclosures include Lisa Mcclain, Valerie Hoyle, Robert B. Aderholt. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade GlaxoSmithKline PLC ADR (GSK) more?
Across disclosed GlaxoSmithKline PLC ADR (GSK) trades, 18% were by Democrats and 82% by Republicans, led by Republicans (82%).
What is the most recent congressional GlaxoSmithKline PLC ADR (GSK) trade?
The most recent disclosed GlaxoSmithKline PLC ADR (GSK) trade was a sale by Lisa Mcclain, filed Nov 20, 2025.
Browse all stocks Congress tradesCongressional trading overviewGlaxoSmithKline PLC ADR (GSK) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.